Press release
Immunicum AB (publ) Announces Upcoming Presentations at Conferences in May
GOTHENBURG, Sweden, April 24, 2017 - Immunicum AB (publ; First North Premier: IMMU.ST) a biopharmaceutical company advancing a novel immuno-oncology treatment against a range of solid tumors, today announced that Carlos de Sousa, MD, CEO of Immunicum, has been invited to present at the following upcoming investor conferences:
Phacilitate "Investment for Advanced Therapies"
Date: May 3, 2017
Presentation Time: 4:00 pm CET
Venue: CMS Cameron McKenna Offices, Cannon Place, London, United Kingdom
BioEquity
Date: May 22-23, 2017
Presentation Time: May 22 at 3:40 pm CET
Venue: Marriott Rive Gauche, Paris, France
Swedish-Austrian Investment Matching
Date: May 23, 2017
Presentation Time: 11:00 am CET
Venue: Schwedenhaus, Vienna, Austria
About Immunicum AB (publ)
Immunicum AB (First North Premier: IMMU.ST) is a clinical stage Company developing novel immuno-oncology therapies against a range of solid tumors. The Company's lead compound, INTUVAX® is currently being evaluated in clinical trials for the treatment of kidney cancer, liver cancer and gastrointestinal stromal tumors. INTUVAX® was designed to combine the best of two worlds: a cost-effective cell-based (allogeneic) and off-the-shelf therapy that is capable of triggering a highly personalized and potentially long-lasting immune response against tumor cells throughout the body. www.immunicum.com
For more information, please contact:
Carlos de Sousa, CEO, Immunicum
Telephone: +46 (0) 31 41 50 52
E-mail: info@immunicum.com
Media Contact
MacDougall Biomedical Communications
Gretchen Schweitzer or Stephanie May
Telephone: +49 89 2424 3494 or + 49 175 571 1562
E-mail: gschweitzer@macbiocom.com
The Company's Certified Adviser is Redeye AB
Telephone: +46 (0) 8 545 013 31
www.redeye.se